Mito-FLAG regimen
WikiDoc Resources for Mito-FLAG regimen |
Articles |
---|
Most recent articles on Mito-FLAG regimen Most cited articles on Mito-FLAG regimen |
Media |
Powerpoint slides on Mito-FLAG regimen |
Evidence Based Medicine |
Cochrane Collaboration on Mito-FLAG regimen |
Clinical Trials |
Ongoing Trials on Mito-FLAG regimen at Clinical Trials.gov Trial results on Mito-FLAG regimen Clinical Trials on Mito-FLAG regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mito-FLAG regimen NICE Guidance on Mito-FLAG regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mito-FLAG regimen Discussion groups on Mito-FLAG regimen Patient Handouts on Mito-FLAG regimen Directions to Hospitals Treating Mito-FLAG regimen Risk calculators and risk factors for Mito-FLAG regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for Mito-FLAG regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Mito-FLAG regimen refers to a regimen consisting of mitoxantrone, fludarabine, cytarabine as bolus (B) or continuous infusion (CI) and granulocyte- colony stimulating factor (G-CSF) in patients with recurrent and refractory acute myeloid leukemia (AML).[1]
Regimen
MitoMitoxantrone FLFludarabine ACytarabine (AraC) GGranulocyte- colony stimulating factor
Indications
- Recurrent and Refractory acute myeloid leukemia (AML)[1]